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Introduction: current challenges in
type 1 diabetes
Diabetes affects 246 million people worldwide and, of
these, approximately 22 million adults and 0.4 million
children have type 1 diabetes (1). The impact of diabe-
tes-related complications on patients and healthcare
systems is signiﬁcant, with reported cumulative inci-
dences of proliferative retinopathy, nephropathy and
cardiovascular disease (CVD) of 47%, 17% and 14%,
respectively, after 30 years of diabetes (2).
Type 1 diabetes is an autoimmune disease, in which
environmental factors are thought to trigger the auto-
immune destruction of pancreatic b-cells in genetically
susceptible individuals. Although great progress has
been made to date in identifying genetic markers
(3,4), widespread genetic screening for susceptibility
to the disease is not yet possible. In young adults, there
is evidence that the onset of type 1 diabetes may be
progressive and characterised by a slower decline in
b-cell function compared with children and adoles-
cents (5). Importantly, data from the Diabetes Control
and Complications Trial (DCCT) suggest that residual
b-cell function is associated with improved outcomes,
such as better glycaemic control and lower risk for
hypoglycaemia and chronic complications (6).
Evidence also shows that optimisation of glycaemic
control at an early stage signiﬁcantly reduces the risk
of microvascular and macrovascular complications, as
clearly demonstrated in the DCCT and its long-term
follow-up study, the Epidemiology of Diabetes Inter-
ventions and Complications (EDIC) trial (7–9).
Despite the clear beneﬁts of intensive glycaemic con-
trol, there is still a large gap between evidence and
practise, with the majority of patients not reaching tar-
gets. In the recent DCCT-EDIC⁄EDC analysis,
81–87% of patients had an HbA1c > 7.0% (2), which
is consistent with the UK ﬁndings of up to 74%
of patients with HbA1c > 7.5% (10). There are a num-
ber of barriers to glycaemic control in type 1 diabetes,
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The Diabetes Control and Complications Trial (DCCT) led to considerable improve-
ments in the management of type 1 diabetes, with the wider adoption of intensive
insulin therapy to reduce the risk of complications. However, a large gap between
evidence and practice remains, as recently shown by the Pittsburgh Epidemiology
of Diabetes Complications (EDC) study, in which 30-year rates of microvascular
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challenges that patients and practitioners face in the day-to-day management of
the disease. These barriers include reaching glycaemic goals, overcoming the reality
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As practitioners, the question remains: how do we help patients with type 1 diabe-
tes manage glycaemia while overcoming barriers? In this article, the Global Part-
nership for Effective Diabetes Management provides practical recommendations to
help improve the care of patients with type 1 diabetes.
What’s known
• Considerable gaps in the care of adult patients
with type 1 diabetes remains, with a high
proportion of patients developing diabetes-related
complications.
• The majority of patients do not achieve glycaemic
goals because of barriers related to insulin dose
adjustment, self-monitoring of blood glucose and
fear of hypoglycaemia.
• Living with diabetes is not easy, and achievement
of glycaemic goals requires the patient to
undertake self-care behaviours with relentless
vigilance.
• Structured education supported by a
multidisciplinary team approach can play an
integral role in helping overcome these barriers.
What’s new
• This article provides guidance on where gaps in
care remain and how to address them based on
recent evidence.
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and the complexity and demands of day-to-day man-
agement, in particular the need for frequent self-moni-
toring of blood glucose (SMBG) and regular
adjustments in insulin dosing. These challenges have
an enormous impact on patient quality of life and
healthcare costs are also considerable (11). In the
future, we hope to be able to prevent this condition
with advances in transplantation techniques or new
agents. However, for practitioners involved in diabetes
care at this time, the question remains: how do we
help patients with type 1 diabetes to better manage
glycaemia to reduce complications and improve
quality of life? To facilitate this, we must be able to
translate what we have learned in the clinical trial set-
ting to the clinic and it is this approach that underlies
the recommendations in this article.
The Global Partnership for Effective Diabetes
Management is a multidisciplinary group of health
practitioners from leading health institutions and
research organisations around the world. Since 2004,
the main remit of our group has been to facilitate
improvements in diabetes care through educational
initiatives. While our previous publications have
focused on type 2 diabetes (12,13), we recognise the
considerable overlap, as well as important differences,
between optimal patient management practices in type
1 and type 2 diabetes. We have therefore broadened
our scope to provide practical guidance on the day-to-
day management of patients with type 1 diabetes, with
key recommendations summarised in Table 1. Because
of the wide range of issues faced by patients with type
1 diabetes, this article will focus speciﬁcally on adult
care. While the implementation of some recommen-
dations may not be possible in all regions, we hope
this article serves as a benchmark for the management
of all patients with type 1 diabetes.
Managing hyperglycaemia in type 1
diabetes
Early optimisation of glycaemic control
Optimisation of glycaemic control at an early stage
of the disease is the most fundamental aspect of care
in type 1 diabetes for preventing microvascular and
macrovascular complications, as shown in the pivotal
DCCT⁄EDIC study. In the DCCT, patients with type
1 diabetes randomised to intensive therapy (‡ 3 insu-
lin injections per day or pump therapy) had tighter
glycaemic control than those who received conven-
tional treatment (1–2 insulin injections per day)
(mean HbA1c: 7.1% vs. 9.1%, respectively) (7).
Intensive treatment signiﬁcantly reduced the inci-
dence of retinopathy by 76%, the progression of reti-
nopathy by 54%, the development of proliferative or
severe non-proliferative retinopathy by 47%, the
occurrence of microalbuminuria by 39%, of
nephropathy by 54% and of clinical neuropathy by
60% (7). The difference in HbA1c between the
groups accounts for > 90% of the beneﬁt associated
with intensive therapy (14). Later, with extended fol-
low up, DCCT⁄EDIC showed that non-fatal myocar-
dial infarction, stroke or death from CVD was
reduced by 57% and occurrence of any CVD event
was reduced by 42% (Figure 1) (8).
The need to optimise glycaemic control as early as
possible is also supported by the ‘metabolic memory’
or ‘legacy effect’ observed in DCCT⁄EDIC, where the
beneﬁt of intensive glycaemic control on the risk of
complications was found to endure even after HbA1c
levels subsequently increased. For example, the
reduced risk of retinopathy associated with intensive
insulin therapy persisted for up to 10 years in the
observational follow-up EDIC study, despite the con-
vergence of HbA1c levels in the intensive and conven-
tional groups (HbA1c 8.0%; Figure 2) (9).
Despite the known beneﬁts of glycaemic control,
many patients do not reach glycaemic targets
(Table 2), with hypoglycaemia or even fear of hypo-
glycaemia being one of the major barriers. Other
barriers include the complexity of some regimens,
causing some patients to regularly omit insulin.
Additional obstacles include poor adherence to
treatment, lack of social support and lack of access
to a specialist care centre, as well as psychological
barriers (15), which are discussed later in this
article. Individuals with poor glycaemic control are
at an increased risk of complications and should
therefore be aiming for as good glycaemic control as
possible.
Recommendation: Aim for as good glycaemic con-
trol as possible while minimising the risk of hypo-
glycaemia.
DCCT/EDIC showed not only the importance of
early glycaemic control for the prevention of compli-
cations, but that it can slow the progression of
complications. For example, in patients with retinop-
athy at baseline in the DCCT, intensive insulin ther-
apy slowed progression by 54% (7). The beneﬁts of
early optimisation of glycaemic control were most
recently demonstrated in the combined analysis of
data from DCCT⁄EDIC and the ‘real world’ observa-
tional EDC study (2). After 30 years of diabetes, the
cumulative incidences of proliferative retinopathy,
nephropathy and CVD were substantially lower in
the DCCT intensive therapy group (21%, 9% and
9% respectively) compared with the DCCT conven-
tional group (50%, 25% and 14%) or the EDC
cohort (47%, 17% and 14%) (Figure 3) (2). (HbA1c
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Figure 1 DCCT⁄EDIC: Cumulative incidence of any CVD event with intensive vs. conventional insulin treatment in
patients with type 1 diabetes (n = 1397) (8). MI, myocardial infarction. *Intensive vs. conventional treatment. Copyright
ª 2005 Massachusetts Medical Society. All rights reserved.
A 
B 
Figure 2 EDIC study: (A) Cumulative incidence of retinopathy (n = 1349) and (B) HbA1c values (n = 1211) over 10 years
after the DCCT trial in which patients with type 1 diabetes were treated with intensive vs. conventional insulin therapy (9).
(A) Error bars are 95% conﬁdence intervals. (B) Box presents quartiles of distribution; vertical lines show the 95th and 5th
percentiles; horizontal line is median; + indicates mean. Copyright ª 2008 American Medical Association. All rights reserved.
Table 1 Practical recommendations for the management of adults with type 1 diabetes
Aim for as good glycaemic control as possible while minimising the risk of hypoglycaemia.
Ensure regular and appropriate monitoring for complications.
Initiate an intensive basal-bolus insulin regimen as early as possible.
Provide all patients with a structured educational programme at initiation of insulin and thereafter.
Ensure that self-monitoring is universally adopted as an integral part of insulin therapy.
Provide education about prevention, recognition and treatment of hypoglycaemia at initiation of insulin therapy and thereafter.
Manage all cardiovascular risk factors.
Explore psychological issues associated with type 1 diabetes and treat⁄refer as appropriate.
Adopt a multidisciplinary team approach with shared goals and recommendations.
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and fell by 0.5% thereafter.) In light of these data,
it is clearly important to identify complications and
associated risk factors as early as possible so that they
may be managed appropriately and effectively. It
may be necessary to reorganise clinical systems to
ensure that regular surveillance for complications
becomes a routine part of care. Many guidelines
recommend annual screening for microvascular and
macrovascular complications in adults with type 1
diabetes (16–18). Recent advice published by the
American Diabetes Association is shown in Table 3
(16). If complications are present, interventions to
reduce the risk of progression should be imple-
mented as soon as possible and patients referred to
specialist care as appropriate.
Recommendation: Ensure regular and appropriate
monitoring for complications.
Insulin therapy
Initiation of insulin
Intensive insulin therapy using a basal-bolus
approach, whether as multiple daily injections or
pump therapy, is considered the best treatment for
individuals with type 1 diabetes regardless of age
(16,17,19). This is because it provides greater glycae-
mic control and has been shown to reduce the risk
of complications compared with conventional ﬁxed-
dose regimens (7,8), most recently shown in the
DCCT⁄EDIC-EDC analysis (2). While achieving
good glycaemic control is important in all age
groups, it is of particular importance in children
with type 1 diabetes, as they face the longest dura-
tion of the disease. Generally available insulin prepa-
rations are summarised in Table 4, along with their
pharmacokinetic proﬁles. The choice of insulin and
mode of delivery should be guided by factors such as
age, lifestyle, general health, motivation, ability for
self-management and diet, as well as availabil-
ity⁄accessibility (17). Consideration should be given
to risk of hypoglycaemia with, for example, longer-
acting insulin analogues (glargine and detemir) being
preferable to intermediate-acting human insulin
[neutral protamine Hagedorn (NPH)], as they
are associated with reduced risk of hypoglycaemia
(20–25), including nocturnal hypoglycaemia (24).
Rapid-acting insulin analogues (lispro, aspart and
glulisine) may be preferred over regular human insu-
lin, as they have been associated with greater
improvements in HbA1c with reduced risk of hypo-
glycaemia (26,27).
A recent meta-analysis found that glycaemic control
was signiﬁcantly better with continuous subcutaneous
insulin infusion (CSII) compared with multiple daily
injections in adults with type 1 diabetes who had
severe hypoglycaemia, with a difference in HbA1c of
0.62% (28). The study also reported a threefold reduc-
tion in severe hypoglycaemia with CSII compared with
multiple daily injections. Patients with the highest
rates of initial severe hypoglycaemia had the greatest
reduction in events. Thus, CSII using a pump device
may be preferable over multiple injections in some
patient groups, such as those with poor glycaemic
control and individuals experiencing frequent severe
hypoglycaemia or requiring greater lifestyle ﬂexibility
(28–30). Insulin pumps also have a number of practi-
cal advantages which can mean greater lifestyle ﬂexi-
bility for the patient in terms of dietary freedom,
activity and a general improvement in quality of life.
However, one of the main drawbacks of pump therapy
is cost, which is a barrier for many patients worldwide.
There may be a misconception that intensive insu-
lin therapy is not necessary at diagnosis and particu-
larly in the ‘honeymoon period’ because of the
residual b-cell function⁄insulin secretion that persists
months after diagnosis in some individuals with type
1 diabetes. However, studies such as the DCCT have
Table 2 Glycaemic targets for individuals with type 1 diabetes
ADA (16) CDA (17) IDF (51) NICE (UK) (18)
HbA1c < 7.0% £ 7.0% 6.2–7.5% £ 6.5–7.5%
Fasting preprandial glucose, mg⁄dl (mmol⁄l) 70–130 (3.9–7.2) 72–126 (4.0–7.0) 91–120 (5.1–6.5) 72–144 (4.0–8.0)
Postprandial glucose, mg⁄dl (mmol⁄l) < 180* (< 10.0) 90–180
 (5.0–10.0) 136–160
 (7.6–9.0) < 180
 (< 10.0)
ADA, American Diabetes Association; CDA, Canadian Diabetes Association; IDF, International Diabetes Federation; NICE, National Institute for Health and Clinical
Excellence.
The CDA guidelines note that HbA1c goals and strategies must be tailored to the individual with diabetes, with consideration given to individual risk factors.
ADA and CDA glycaemic targets are for type 1 and type 2 diabetes.
*Peak postprandial capillary plasma glucose.
90–144 mg⁄dl (5.0–8.0 mmol⁄l) if HbA1c target not being met.
Capillary postprandial glucose 1–2 h after meal.
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initiated as soon as possible to prevent diabetes-
related complications (8,9) and preserve b-cell func-
tion (6). This approach should be the case in the
great majority of individuals, regardless of the mode
of insulin delivery used.
Recommendation: Initiate an intensive basal-bolus
insulin regimen as early as possible.
Insulin dose adjustment
It is important that patients adjust their insulin
doses appropriately in response to factors such as
carbohydrate intake, lifestyle, exercise and intercur-
rent illness to minimise the risk of hypo- or hyper-
glycaemia. As described above, insulin pumps may
allow greater ﬂexibility of dosing, but as all patients
will not have access to pump therapy, alternative
strategies are needed and education is required for
all patients.
Modiﬁcation of insulin dosages based on diet and
exercise can be challenging for patients and should
be considered an essential part of patient education.
Structured education programmes have been demon-
strated to have substantial beneﬁts in terms of
outcomes (31–35). For example, the UK-based Dose
Adjustment For Normal Eating (DAFNE) programme
has been shown to improve glycaemic control and
quality of life while saving costs, without increasing
the risk of severe hypoglycaemia (34,35). Similarly,
in the Dusseldorf Diabetes Treatment and Teaching
Programme (DTTP), which involves a 5-day inpa-
tient course for individuals with type 1 diabetes,
HbA1c fell signiﬁcantly from 8.1% to 7.3% over the
subsequent year, as did the number of severe hypo-
glycaemic episodes (0.37 vs. 0.14 events per patient-
year) (31). These types of programmes demonstrate
that appropriate education can improve glycaemic
control while giving the individual more ﬂexibility in
terms of diet rather than having to adhere to rigid
calorie control and ﬁxed insulin doses. Other impor-
tant considerations include the use of carbohydrate
counting, a common meal-planning method used by
patients, which must of course be adapted to local
diet and lifestyle. Appropriate adjustment of insulin
doses surrounding exercise is also important. Despite
the well-known health beneﬁts of exercise, 64% of
patients with type 1 diabetes do not achieve recom-
mended physical activity levels because of barriers
such as fear of hypoglycaemia (36,37). In addition,
many patients may not know the effect of factors
such as exercise or alcohol on glucose levels and the
need for appropriate adjustment of insulin therapy,
highlighting the importance of education on this
subject.
Another consideration is how to adjust insulin
dosages during intercurrent illness. In some cases,
patients may cease taking insulin altogether, particu-
larly if they are unable to ingest food. This can lead
to serious metabolic derangements including diabetic
ketoacidosis (DKA). In patients hospitalised for DKA,
inadequate insulin dosing was found to be the identi-
ﬁable cause of DKA in up to 45% of cases (38). It is
also important that patients are aware that infection
generally exacerbates hyperglycaemia and, thus, they
should monitor their glucose levels and continue to
take insulin as appropriate, even if their caloric con-
sumption is reduced. Ideally, these types of issues
Figure 3 Cumulative incidences of (A) proliferative
retinopathy or worse, (B) nephropathy and (C) CVD over
time in the DCCT intensive therapy group, DCCT
conventional therapy group and EDC cohort (2).
Nephropathy was deﬁned as albumin excretion rate
‡ 300 mg⁄24 h, serum creatinine ‡ 2m g⁄dl, or dialysis or
renal transplant. CVD was deﬁned as: non-fatal myocardial
infarction or stroke, CVD death, subclinical myocardial
infarction, angina, angioplasty or coronary artery bypass.
Copyright ª 2009 American Medical Association. All rights
reserved.
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self-management education and reiterated during
regular reviews.
Recommendation: Provide all patients with a
structured educational programme at initiation of
insulin and thereafter.
Self-monitoring of blood glucose
Self-monitoring of blood glucose is so fundamental
that insulin therapy should always comprise insulin
therapy plus SMBG. Patients should receive appro-
priate training in SMBG when insulin therapy is ini-
tiated and periodically thereafter. Self-monitoring
provides patients with immediate feedback of the
effects of insulin dosage and timing, diet, exercise
and stress on glucose levels, providing valuable infor-
mation on pre- and postprandial and nocturnal glu-
cose levels (39). In addition, self-monitoring should
be supported by the diabetes team through discus-
sion of results with patients during each clinic visit
to help improve the efﬁcacy and safety of insulin
therapy. It should also be emphasised to patients that
self-monitoring is not an end in itself, but that the
results should be acted on. Clear guidance should be
given to patients as to how to adjust insulin dose in
response to their results. This should include advice
on how to avoid overcorrection when, for example,
patients administer an inappropriately large dose of
rapid-acting insulin in response to high blood glu-
cose levels.
Patients should monitor glucose levels at least
three times per day or more (16–18) and testing
should include pre- and postprandial measurements
(40). Self-monitoring allows patients to adjust insulin
doses based on day-to-day requirements, depending
on factors such as activities and meals. Karter et al.
found adults with type 1 diabetes who self-monitored
three or more times per day had an HbA1c 1% lower
than patients who monitored less frequently or
not at all (41). More frequent monitoring should be
considered in certain circumstances, such as hypo- or
hyperglycaemic symptoms, hypoglycaemia unaware-
ness, intercurrent illness, gastroparesis, pregnancy,
brittle diabetes or rigorous physical activity (39).
Despite the clear beneﬁts of regular monitoring,
SMBG places complex behavioural demands on
patients, and up to 64% of individuals do not regu-
larly self-monitor (2). There are a range of barriers
to self-monitoring, including patient motivation, psy-
chological barriers, cost, socioeconomic status and
education level (39,42). It is important that patients
learn to overcome these barriers and are provided
with appropriate support to do so. For example, cost
is a difﬁcult barrier to overcome, but there is evi-
dence that providing patients with free testing strips
improves glycaemic control and compliance with
self-monitoring (43).
Recommendation: Ensure that self-monitoring is
universally adopted as an integral part of insulin
therapy.
Recent progress has led to the development of con-
tinuous glucose monitoring (CGM) (44–48), which
appears to have certain beneﬁts in regions where it is
available. Studies in adults with poorly controlled
type 1 diabetes (HbA1c ‡ 7.0%) have shown a signiﬁ-
cant reduction in HbA1c ()0.5%) with CGM com-
pared with SMBG over 26 weeks, without an increase
in hypoglycaemia (46,48). These effects were sus-
tained for up to 1 year (48). Furthermore, in adults
with well-controlled type 1 diabetes using CGM,
HbA1c levels were maintained at baseline values
(6.4%), with less hypoglycaemia, whereas HbA1c
rose (from 6.5% to 6.8%) in patients who used
SMBG over 26 weeks (47). CGM also limits glycaemic
excursions (45). However, CGM is not currently
Table 3 Screening for complications in adults with type 1 diabetes; recommendations from the American Diabetes Association (16)
Care Screening
Retinopathy Refer for an initial dilated and comprehensive eye examination within 5 years after diabetes onset and annually thereafter.
Consider less frequent examination (every 2–3 years) following one or more normal eye examinations.
More frequent examinations required if retinopathy is progressive.
Chronic kidney
disease
Perform an annual urine albumin excretion test in patients with type 1 diabetes of ‡ 5 years’ duration.
Measure serum creatinine at least annually, regardless of degree of urine albumin excretion.
Neuropathy Screen all patients for distal symmetrical polyneuropathy at diagnosis and at least annually thereafter using simple clinical tests sucha s
pinprick sensation, vibration perception (using a 128 Hz tuning fork), 10 g monoﬁlament pressure sensation at the distal plantar aspect
of both great toes and metatarsal joints, and assessment of ankle reﬂexes.
Institute screening for signs and symptoms of cardiovascular autonomic neuropathy 5 years after diagnosis of type 1 diabetes.
Dyslipidaemia Measure fasting lipid proﬁle at least annually in most adult patients.
Aggressively treat lipid and blood pressure abnormalities.
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in the future. Moreover, a closed loop or partially
closed loop system including CGM in tandem with
an insulin pump may become available (49).
Hypoglycaemia
Hypoglycaemia is a common problem in type 1
diabetes that can affect all aspects of life including
personal relationships, employment, driving, physical
activity and travel (50). The degree of hypoglycaemia
can vary hugely, from no symptoms to a serious life-
threatening condition. Fear of hypoglycaemia in both
patient and physician can prevent individuals from
achieving optimal glycaemic control and can have
a major impact on quality of life. Guidelines generally
deﬁne hypoglycaemia as plasma glucose < 4.0 mmol⁄l
(< 72 mg⁄dl) (16,17,51). However, patients may not
consider low blood glucose levels as a sign of hypo-
glycaemia if they are asymptomatic; thus, the impor-
tance of monitoring and keeping blood glucose levels
above this threshold, regardless of presence or absence
of symptoms, should be emphasised.
In the DCCT, severe hypoglycaemia was three
times higher with intensive therapy compared with
conventional therapy (Figure 4) (52,53), although the
actual frequency may be even higher outside the clin-
ical trial setting (54). Yet, it should be appreciated
that the absolute frequency of severe hypoglycaemia
may be lower with the use of analogue insulin ther-
apy. Patients who experience severe hypoglycaemia
are at increased risk of subsequent episodes, with
almost one-third experiencing a second episode
within 4 months (53). Nocturnal hypoglycaemia is
also a signiﬁcant health burden, with almost half of
severe hypoglycaemic episodes occurring at night
(52). Risk factors associated with hypoglycaemia are
numerous but include strict glycaemic control
(HbA1c < 6.0%), prior episode of severe hypoglyca-
emia, longer duration of diabetes, autonomic neu-
ropathy and hypoglycaemia unawareness (17,50,53).
Of note, in the DCCT, intensively treated patients
with greater residual b-cell function (C-peptide
0.21–0.5 nmol⁄l) had a signiﬁcantly lower rate of
hypoglycaemia compared with those with less or no
residual b-cell function (0.07 vs. 0.16–0.21 events per
patient-year) (55).
Overall, it is imperative that patients receive
appropriate information about hypoglycaemia, which
should take place upon diagnosis of diabetes and
regularly thereafter at follow-up consultations. As
mentioned above, SMBG can provide valuable infor-
Table 4 Pharmacokinetics of human insulin and analogues (87) (may depend on local availability)
Class of insulin Formulation Onset (min) Peak (h) Duration (h)
Basal insulins
Long-acting analogues Insulin glargine 66 – Up to 24
Insulin detemir 48–120 – Up to 24
Intermediate-acting human NPH, human 60–120 6–14 16–24
Prandial insulins
Rapid-acting analogues Insulin lispro 15–30 0.5–2.5 3–6.5
Insulin aspart 10–20 1–3 3–5
Insulin glulisine 10–15 1–1.5 3–5
Short-acting human Regular, human 30–60 1–5 6–10
Premixed insulins
Premixed analogues BiAsp 70⁄30 10–20 1–4 Up to 24
Insulin lispro 75⁄25 15–30 1–6.5 Up to 24
Insulin lispro 50⁄50 15–30 0.75–13.5 Up to 24
Premixed human 70% NPH⁄30% regular 30–60 2–16 Up to 18–24
BiAsp, biphasic insulin aspart; NPH, neutral protamine Hagedorn.
Figure 4 Risk of severe hypoglycaemia vs. HbA1c in the
intensive (•) and conventional (s) groups during the
DCCT (n = 1441) (53). Copyright ª 1997 American
Diabetes Association. Reprinted with permission from The
American Diabetes Association.
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be as vigilant of low glucose as high glucose levels.
Patients should be reminded to avoid behaviours
that can contribute to hypoglycaemia, such as taking
excess insulin, delaying or missing meals, etc. In
addition, not only is mis-timing insulin⁄food intake
around exercise a risk for hypoglycaemia (52) but
patients are often unaware that hypoglycaemia can
occur for up to 12 h after exercise; they should
therefore be advised on appropriate action including
additional monitoring before bed and appropriate
increased food intake. Alcohol consumption can also
lead to hypoglycaemia and impair recovery from a
hypoglycaemic episode; the importance of not omit-
ting food when drinking should be emphasised to
patients. Additionally, patients should be advised to
have a glucagon emergency kit on hand for severe
hypoglycaemic episodes.
Recommendation: Provide education about pre-
vention, recognition and treatment of hypoglyca-
emia at initiation of insulin therapy and thereafter.
Hypoglycaemia unawareness is an important con-
sideration, as it can increase the risk of severe hypo-
glycaemia sixfold (50). A retrospective survey of
individuals with type 1 diabetes suggests that as many
as 20% of patients may be affected (56). In these
individuals, changes in the symptom proﬁle may
hamper the recognition of impending hypoglycaemia;
for example, neuroglycopenic symptoms (poor con-
centration, drowsiness and difﬁculties in speech and
physical coordination) become more prominent,
whereas autonomic symptoms (anxiety, palpitations,
sweating and hunger) are blunted or even absent
(50). In terms of education, those with hypoglyca-
emia unawareness will require additional help in rec-
ognising its onset, as signs and symptoms are altered.
Enabling patients to avoid mild hypoglycaemia can
subsequently improve awareness (57,58).
Managing cardiovascular risk factors
Although the link between type 2 diabetes and CVD
is well-known, the increased risk of CVD in type 1
diabetes may be overlooked. However, men with type
1 diabetes have a 3.6-fold higher risk of CVD and
women a 7.7-fold higher risk than those without dia-
betes (59). Furthermore, men with type 1 diabetes
aged 45–55 years have the same absolute risk of
CVD as men 10–15 years older without diabetes,
with an even greater difference in women (59).
There is debate concerning the question of whether
type 1 diabetes is itself a risk factor for CVD. Evi-
dence suggests that the increase in CVD risk in type
1 diabetes is largely associated with nephropathy
(60–64). Indeed, it has been proposed that microal-
buminuria and CVD may share common pathophysi-
ological processes, such as endothelial dysfunction
and chronic low-grade inﬂammation (65). Further-
more, data from a large type 1 diabetes cohort have
shown that relative mortality from CVD was 37 times
greater in those with proteinuria compared with the
general population, whereas CVD mortality was only
4.2 times greater in those without proteinuria com-
pared with the general population (66).
However, other risk factors are also present in type
1 diabetes, including hyperglycaemia itself, as shown
in the DCCT⁄EDIC (8,67). It is notable that the
metabolic syndrome is becoming more prevalent in
the type 1 diabetes population (68) and is associated
with an additional 2.5-fold increased risk of cardio-
vascular and diabetes-related mortality (adjusted for
traditional risk factors and diabetic nephropathy)
(69). Lifestyle factors may also play a role: adults
with long-standing type 1 diabetes have been found
to consume a high-fat atherogenic diet compared
with those without diabetes (70).
Given the increased risk of CVD, it is apparent
that more could be done to address cardiovascular
risk factors in type 1 diabetes. In the Pittsburgh Epi-
demiology of Childhood-Onset Diabetes Complica-
tions Study, the event rate of coronary artery disease
did not decline over the 30-year follow-up period
(1950–1980), despite signiﬁcant reductions over time
in other complications such as renal failure and neu-
ropathy (71). Additional analyses indicated inade-
quate management of cardiovascular risk factors in
this population, with sub-optimal control of hyper-
tension in 72% and of hypercholesterolaemia in 94%
of patients (72). Although there is generally a lack of
data from large prospective studies of cardiovascular
medications in type 1 diabetes, statin therapy has
been shown to be as effective in type 1 diabetes as in
type 2 diabetes and should be considered in patients
with diabetes at sufﬁciently high risk of vascular
events (73). Overall, it is important to monitor and
manage cardiovascular risk factors in patients with
type 1 diabetes as appropriate. While data are lim-
ited, patients with type 1 diabetes of a duration of at
least 15 years and over 30 years of age should be
considered at high risk of CVD (17).
Recommendation: Manage all cardiovascular risk
factors.
Psychological aspects of the disease
It is important for practitioners to be aware not only
of the heavy burden that patients with type 1 diabetes
face in terms of practical day-to-day management but
also of the signiﬁcant psychological impact of the
disease. Recent evidence suggests that the prevalence
of depression and anxiety symptoms is considerably
312 Improving management of type 1 diabetes
ª 2010 Blackwell Publishing Ltd Int J Clin Pract, February 2010, 64, 3, 305–315higher in patients with type 1 diabetes compared with
the general population (74,75). The consequences
of psychiatric disorders in type 1 diabetes are far-
reaching and are associated with hyperglycaemia and
treatment non-adherence as well as with the long-
term complications of the disease (76–83). Some
groups may be more vulnerable to psychiatric prob-
lems, such as teenage girls and women who are
particularly prone to eating disorders and may omit
insulin doses as a means of weight control (84,85),
which can adversely affect optimal management and
outcomes (86) in type 1 diabetes.
Guidelines recommend that psychological screen-
ing should generally be a routine part of diabetes
management (16–18). The overall challenge for all
members of the multidisciplinary team is to be aware
of and able to recognise the psychological impact of
the disease and to refer patients to specialist care
when appropriate. As mentioned above, a psycholo-
gist or psychiatrist should be considered part of the
multidisciplinary team wherever possible.
Recommendation: Explore psychological issues
associated with type 1 diabetes and treat⁄refer, as
appropriate.
A team approach to diabetes care
As described above, there are many complexities
involved in treating patients with type 1 diabetes and
helping them to achieve and maintain their glycae-
mic targets. Therefore, adopting a team approach
that involves a broad range of disciplines is essential.
Depending on circumstances and available resources,
the multidisciplinary team should include the
patient, diabetes specialist, primary care physician,
nurse, dietitian, podiatrist and psychologist⁄psychia-
trist, as well as family and friends. All members of
the team should work together to ensure continuity
of care. Communication and coordination within the
team are also imperative to ensure that all members
share and are working towards the same treatment
targets and recommendations.
Recommendation: Adopt a multidisciplinary team
approach with shared goals and recommendations.
Conclusion
While studies such as DCCT⁄EDIC have helped
inform and improve diabetes management, gaps in
care still remain, with glycaemic – as well as cardio-
vascular – targets still not being met by a considerable
proportion of patients. We hope the recommen-
dations presented here by the Global Partnership for
Effective Diabetes Management provide guidance on
where gaps remain and how to address them based
on recent evidence. As mentioned above, the manage-
ment of type 1 diabetes is complex for both patients
and health professionals, and it is through the multi-
disciplinary team that these recommendations can be
best implemented.
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